Global Aminoglycosides Market Revenue Grows at a CAGR of 4.32%

Introduction

Straits Research released its highly anticipated report, “Global Aminoglycosides Market Size & Outlook, 2026-2034”. According to a study, the market size is valued at USD 2.09 billion in 2025 and is projected to expand to USD 3.05 billion by 2034, registering a compound annual growth rate (CAGR) of 4.32%.

Market Dynamics

The global aminoglycosidase market is witnessing steady growth, primarily driven by the rising incidence of bacterial infections and hospital acquired infections worldwide. Aminoglycosides are widely used in the treatment of life threatening infections such as sepsis, tuberculosis, and complicated urinary tract and respiratory infections, especially in intensive care and hospital settings. The increasing prevalence of antimicrobial resistant pathogens has further reinforced the clinical importance of aminoglycosides, as they are often used in combination therapies to enhance antibacterial efficacy.

However, market growth is restrained by the safety concerns associated with aminoglycosides therapy. Adverse effects such as nephrotoxicity and ototoxicity limit long term usage and require careful dose monitoring among elderly patients and those with pre-existing kidney disorders. These safety risks have encouraged physicians to adopt alternative antibiotic classes, thereby restricting broader market expansion. In addition, increasing antimicrobial stewardship programs aimed at reducing unnecessary antibiotic use also reduces prescription volumes.

Despite these challenges, the market presents strong opportunities driven by the growing demand for cost effective generic antibiotics and improved formulations. Advancements in drug delivery systems, such as liposomal and inhaled aminoglycosides, are helping reduce toxicity while improving therapeutic outcomes. Furthermore, expanding healthcare infrastructure, rising access to hospital care, and increasing production of affordable generics in regions such as Asia Pacific, Latin America, and the Middle East are expected to create attractive growth opportunities for key market players in the coming years.

Market Highlights

• Product: The Gentamicin segment dominated the market in 2025, accounting for 31.62% market share.
• Route of Administration: The injectable segment dominated the market in 2025 with a revenue share of 28.75%.
• Application: The skin infection segment is expected to grow at the fastest CAGR during the forecast period.
• Regional Insights: North America dominated the market with a revenue share of 37.48%, due to the widespread availability of aminoglycoside therapies across hospital settings.

Competitive Players

1. Pfizer Inc.
2. Novartis AG
3. Teva Pharmaceutical Industries Ltd.
4. Johnson & Johnson
5. Sanofi
6. Bristol Myers Squibb Company
7. AbbVie Inc.
8. Cipla Limited
9. Sun Pharmaceutical Industries Ltd.
10. Aurobindo Pharma Limited
11. Lupin Limited
12. Zydus Lifesciences Ltd.
13. Viatris Inc.
14. Fresenius Kabi AG
15. Hikma Pharmaceuticals PLC
16. Aspen Pharmacare Holdings Ltd.
17. Zoetis Inc.
18. Zhejiang Hisun Pharmaceutical Co., Ltd.
19. Others

Recent Developments

February 2024: Cipla reinforced its fight against antimicrobial resistance by obtaining approval from India’s CDSCO to launch ZEMDRI (plazomicin) injection, a novel intravenous aminoglycoside antibiotic, for the treatment of complicated urinary tract infections in the Indian market.

Segmentation

1. By Product (2026-2034)
   1. Neomycin
   2. Tobramycin
   3. Gentamicin
   4. Amikacin
   5. Paromomycin
   6. Streptomycin
   7. Kanamycin
   8. Others
2. By Route of Administration (2026-2034)
   1. Injectable
   2. Oral
   3. Topical
   4. Others
3. By Application (2026-2034)
   1. Respiratory Diseases
   2. UTI & Pelvic Diseases
   3. Skin Infection
   4. Veterinary
   5. Others